MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10585-012-9477-1

Медицинская библиотека · Clinical & experimental metastasis · 2012

VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.

Schultze Alexander, Ben Batalla Isabel, Riethdorf Sabine, Bubenheim Michael, Yekebas Emre, Erbersdobler Andreas, Reichelt Uta, Effenberger Katharina E, Schmidt Thomas, Izbicki Jakob R, Bokemeyer Carsten, Pantel Klaus, Fiedler Walter, Loges Sonja

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Blocking angiogenesis by inhibiting VEGF represents an established therapeutic strategy in many cancers. The role of placental growth factor (PlGF) and of its receptor VEGFR-1 in tumor biology remain more elusive. Currently, humanized monoclonal antibodies against PlGF are studied in early phase clinical trials because PlGF inhibition blocked murine tumor growth and angiogenesis. In contrast to mice exclusively expressing one PlGF isoform (PlGF-2), humans can produce four PlGF isoforms (PlGF1-4). Surprisingly nothing is yet known about expression of all four PlGF isoforms in human cancer, because until now mostly total PlGF levels or PlGF-1/2 were analyzed without discriminating further. In this study we determined mRNA expression levels of PlGF1-4 and of VEGFR-1 by QRT-PCR in human esophageal tumor tissue and investigated whether gene expression levels correlate with clinical data. PlGF-1 and -2 were expressed in virtually all analyzable tumors, whereas PlGF-3 and -4 were present in tumors of 59 and 74 % of patients, respectively. MRNA Expression levels of all four splice variants correlated with each other. In contrast, PlGF-1 and -2 mRNA expression was lower in esophageal control tissue and PlGF-3 and -4 mRNA were undetectable. VEGFR-1 was expressed by more than 80 % of patients. Interestingly, VEGFR-1 expression levels significantly correlate with presence of disseminated tumor cells (DTCs) in bone marrow. Patients with DTCs exhibit lower VEGFR-1 mRNA expression than patients without DTCs. Pending validation in other types of cancer, expression levels of VEGFR-1 might be useful as surrogate marker for DTCs.

Для цитирования: Schultze Alexander, Ben Batalla Isabel, Riethdorf Sabine, Bubenheim Michael, Yekebas Emre, Erbersdobler Andreas, Reichelt Uta, Effenberger Katharina E, Schmidt Thomas, Izbicki Jakob R, Bokemeyer Carsten, Pantel Klaus, Fiedler Walter, Loges Sonja. VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.. Clinical & experimental metastasis. 2012. DOI: 10.1007/s10585-012-9477-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.